Early Career Investigator Research at STEM CELLS Translational Medicine
Early Career Investigators (ECIs) are important drivers of scientific discovery but may face hurdles when submitting manuscripts for publication in top-tier journals. To address this concern, STEM CELLS Translational Medicine is accepting and encouraging manuscripts submitted by ECIs. Manuscripts will be subject to the same rigorous peer review as all submissions to the journal. We hope this is just the beginning of our offerings to support ECIs in our community.Latest articles
Background and aims Cord blood infusion is an emerging treatment for cerebral palsy (CP) currently offered in the United States through clinical trials and an expanded access pathway. This study aimed to understand the barriers and facilitators influencing implementation of cord blood treatment for ...
Rodent cell culture models have long underpinned research into nociceptive signaling; however, their limited recapitulation of human nociceptor biology has created a translational gap in analgesic development. While primary human sensory neurons are relevant, their use is hampered by scarcity, ...
Platelet products are essential for preventing and treating bleeding in patients with thrombocytopenia. However, their short shelf life and reliance on voluntary blood donations pose significant challenges to maintaining a stable supply. To overcome these limitations, induced pluripotent stem ...
Background: Human induced pluripotent stem cells (hiPSCs) are essential tools for disease modeling, drug testing, and regenerative medicine. These applications require differentiation of multiple cell lines in parallel, synchronized production of large numbers of hiPSCs and differentiated cells, ...
Diabetic vascular complications remain a major cause of morbidity and mortality, yet the molecular mechanisms underlying endothelial dysfunction in diabetes remain incompletely understood. Endothelial dysfunction is a key contributor to vascular pathology, and patient-derived induced pluripotent ...
Pluripotent stem cell (PSC)-based therapies hold the potential to unlock cures for numerous diseases, including, but not limited to, Parkinson’s disease, macular degeneration, heart failure, type 1 diabetes, and cancer. Yet as protocols to differentiate PSCs into therapeutically useful cell types ...
Most read
Background Red blood cell (RBC) transfusions are essential for treating various medical conditions, but global demand is difficult to meet due to a dwindling donor pool and compatibility issues. Pluripotent stem cells (PSCs) offer a promising alternative of blood dependent on volunteer donors for RBC production, and dogs ...
The use of dental implants to replace lost or damaged teeth has become increasingly widespread due to their reported high survival and success rates. In reality, the long-term survival of dental implants remains a health concern, based on their short-term predicted survival of ~15 years, significant potential for jawbone ...
Background Charcot–Marie–Tooth disease type 1 (CMT1) is a rare, genetically diverse condition and represents the most prevalent form of inherited peripheral neuropathy, characterized by Schwann cell dysfunction resulting in progressive demyelination and muscle wasting. CLZ-2002, an allogeneic Schwann cell-like product ...
Research conducted on the International Space Station (ISS) in low-Earth orbit (LEO) has shown the effects of microgravity on multiple organs. To investigate the effects of microgravity on the central nervous system, we developed a unique organoid strategy for modeling specific regions of the brain that are affected by ...
Background We previously performed a phase II clinical trial involving the intravenous infusion of autologous cord blood mononuclear cells (ACBMNCs) to prevent bronchopulmonary dysplasia in premature infants. We reported the outcomes before discharge and at 2-year follow-up of the enrolled infants. We have reported the ...
Retinal degenerations, comprising a heterogeneous group of disorders culminating in neuroretinal dysfunction, such as inherited retinal dystrophies (IRDs) and age-related retinal degeneration, are among the leading causes of irreversible vision loss worldwide. Restoring visual function through cell replacement therapy ...
-
5.92025 Impact Factor
-
10.02025 CiteScore
Editor-in-Chief
Anthony Atala
Call for Papers
STEM CELLS Translational Medicine is currently seeking submissions on human clinical articles and cord blood. Visit our Call for Papers to learn more and submit your research for an upcoming issue.
Learn more
In the Spotlight: STEM CELLS Translational Medicine Altmetric Highlights
This collection brings together 14 articles from STEM CELLS Translational Medicine that have received notable interest across news outlets, social media, and other online platforms, reflected in their Altmetric Attention scores.
Browse the collection here.
The perfect home for your research
With benefits including a simple submission process, rapid publication, and high ranking, STEM CELLS Translational Medicine is the perfect home for your research. As of May 1st 2025, the journal no longer charges submission fees.
Learn more about publishing with us here.
STEM CELLS Translational Medicine on social media
Join the conversation and follow us on social media.
Sister Journal: STEM CELLS
STEM CELLS focuses primarily on the functional and mechanistic aspects of stem cell biology and the potential of different types of stem cells for therapeutic applications.
Learn more
Email alerts
Register to receive table of contents email alerts as soon as new issues of Stem Cells Translational Medicine are published online.
Sign up
Author resources
Learn about how to submit your article, our publishing process, and tips on how to promote your article.
Find out more
Become a reviewer for STEM CELLS Translational Medicine
STEM CELLS Translational Medicine would like to invite you to review for the journal. Please consider joining us as an ad hoc peer reviewer, where you will be periodically invited to review manuscripts based on your area of expertise.
Learn more about becoming a reviewer
Committee on Publication Ethics (COPE)
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE)
publicationethics.org
Read and Publish deals
Authors interested in publishing in STEM CELLS Translational Medicine may be able to publish their paper Open Access using funds available through their institution’s agreement with OUP.
Find out if your institution is participating
Recommend to your library
Fill out our simple online form to recommend STEM CELLS Translational Medicine to your library.
Recommend now
